SCA
AQST icon

Snowden Capital Advisors’s Aquestive Therapeutics AQST Stock Holding History

Snowden Capital Advisors’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.2K Buy
10,854
+6
+0.1% +$25 ﹤0.01% 1326
2026
Q1 		$45K Buy
10,848
+75
+0.7% +$304 ﹤0.01% 1270
2025
Q4 		$69.6K Buy
+10,773
New +$67.1K ﹤0.01% 1255

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Snowden Capital Advisors's AQST Position: Q2 2026 in Review

Snowden Capital Advisors increased its Aquestive Therapeutics (AQST) stake by 0.06% in Q2 2026, buying an estimated $25 and bringing the position to 10,854 shares worth $45.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1326.

Snowden Capital Advisors first reported a position in AQST in Q4 2025 and has held it in 3 quarters since. The position peaked at $69.6K in Q4 2025. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Snowden Capital Advisors held 10,854 shares of Aquestive Therapeutics worth $45.2K as of Q2 2026.
  • Snowden Capital Advisors bought 6 Aquestive Therapeutics shares in Q2 2026, an estimated $25.
  • Aquestive Therapeutics made up ﹤0.01% of Snowden Capital Advisors's portfolio in Q2 2026, its #1326 holding.
  • Snowden Capital Advisors first reported a position in Aquestive Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Snowden Capital Advisors's Aquestive Therapeutics position peaked at $69.6K in Q4 2025.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.